A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection.

ABSTRACT:

Background

PSA-directed prostate cancer screening leads to a high rate of false positive identifications and an unnecessary biopsy burden. Epigenetic biomarkers have proven useful, exhibiting frequent and abundant inactivation of tumor suppressor genes through such mechanisms. An epigenetic, multiplex PCR test for prostate cancer diagnosis could provide physicians with better tools to help their patients. Biomarkers like GSTP1, APC and RASSF1 have demonstrated involvement with prostate cancer, with the latter two genes playing prominent roles in the field effect. The epigenetic states of these genes can be used to assess the likelihood of cancer presence or absence.

Results

An initial test cohort of 30 prostate cancer-positive samples and 12 cancer-negative samples was used

SUBMITTER: Van Neste L 

PROVIDER: S-EPMC3431995 | biostudies-literature | 2012 Jun

REPOSITORIES: biostudies-literature